Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Generoath
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Generoath is a biotechnology company focused on developing transformative gene therapies for the treatment of hearing loss and other sensory disorders. The company's primary focus is on addressing genetic forms of deafness, specifically targeting mutations in the GJB2 gene, which is a leading cause of congenital hearing impairment. By utilizing advanced adeno-associated virus (AAV) vector technology, Generoath aims to deliver functional genetic material to the inner ear to restore auditory function. The company is currently in the pre-clinical stage, advancing its lead programs toward regulatory filings and clinical trials.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Gene therapyAAV vector
- Industry
- Biotech
Beyond the preview
Go deeper on Generoath.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Generoath.